Skip to content

Urodynamic Changes Following Bladder Injury

Urodynamic Changes Following Bladder Injury During Surgical Management of Placenta Accreta Spectrum: A Multicenter Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04835766
Acronym
Uro-PAS
Enrollment
120
Registered
2021-04-08
Start date
2021-07-01
Completion date
2024-07-31
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Dysfunction, Urodynamic Changes, Urologic Injuries

Brief summary

This study is a unique one as it si done for first time to all patients following bladder injury in PAS surgery. Bladder function will be assessed by urodynamic study.

Detailed description

Patients will be initially assessed by overactive bladder (OAB) and incontinence questionnaire. Examination was done to determine any neurological, or congenital abnormalities. Urodynamic study (UDS) will done for all patients. The patients will be asked to drink fluids to obtain a comfortably full bladder. Initially, a pelvic-abdominal ultrasound was done followed by the UDS. Urodynamic study consisted of uroflowmetry (volume: ≥150 ml and Qmax: 20-30 ml/s); filling cystometry in physiological or medium filling rate of 40 ml/min (using normal saline at room temperature through a double lumen urethral catheter); stress leak test; and pressure flow study. No sedation will be administered during the study as the patient should be aware. The patients were placed in a semi-seated lithotomy position. After a detailed explanation to the patient, the examination will begin by passing a catheter into the bladder (5 Fr) to measure the postvoiding residual urine followed by filling the bladder and measuring the intravesical pressure through the catheter. A rectal catheter was placed for measuring the abdominal pressure. The systems will be always zeroed at the atmospheric pressure. The patients will be periodically asked to cough to check the operation of the equipment and instructed to report her sensations. The volume of the first sensation of filling, first desire (1 s) and second desire (2 s) were recorded. When the bladder was filled up to 150 ml, patients were asked to cough (Valsalva) to predict the stress leakage. If not occur at 150 ml, the bladder was refilled, and the stress test was repeated until the leakage occurred or the bladder capacity was reached. Additionally, any unidentified involuntary detrusor contractions will be noted. When the patient had the urge to void, the permission for voiding will be given. Then voiding cystometrogram (pressure-flow) was performed and the urodynamic parameters, such as maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax) will be observed.

Interventions

DIAGNOSTIC_TESTUrodynamic study

Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years

Inclusion criteria

* Age 20-40 years * Placenta accreta managed either by cesarean hysterectomy or by uterine sparing conservative treatment * Bladder injury was diagnosed and repaired during surgery 6 months ago.

Exclusion criteria

* Patients with neurological problems * Presence of congenital urinary system anomalies * Urinary tract infections (UTIs) * Previous urologic surgeries * Patients with stone bladder or tumour * Diabetic patients

Design outcomes

Primary

MeasureTime frameDescription
Bladder dysfunction6 monthsUroflowmerty measuring the flow of urine in ml per minute
Residual urine volume6 monthsAssessed by ultrasound to measure volume of residual urine
maximum flow rate6 monthsUrodynamic study
Detrusor pressure at maximum flow6 monthsUrodynamic study

Countries

Egypt

Contacts

Primary ContactAyman Dawoog, MD
ayman.dawood@med.tanta.edu.eg+202020972067
Backup ContactAyman Dawood, MD
ayman.dawood@med.tanta.edu.eg+201020972067

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026